Benralizumab
Anti–IL-5Rα monoclonal antibody (ADCC-mediated eosinophil depletion)
- Response rate
- Near-complete eosinophil depletion
- Onset
- 4 weeks
- Route
- SC 30mg every 4–8 weeks
- Line
- 1st-line biologic
- IgM effect
- Reduces polyp score
Evidence summary
Binds IL-5Rα and induces antibody-dependent cellular cytotoxicity (ADCC), depleting eosinophils and basophils. OSTRO trial showed significant NPS and congestion improvement. FDA-approved 2024 for CRSwNP. Unique mechanism achieving near-complete tissue eosinophil depletion.
Molecular targets (2)
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| IL-5 | Eosinophil survival factor | Elevated | established |
| Eosinophils | Effector granulocytes | Massively infiltrated in tissue | established |